|
|||||
|
|
| rhTPO等四种升血小板药物临床应用评价及经济学评估 | |
| 引用本文： | 郭代红,邢午宏,陈超,王伟兰,于力,刘皈阳.rhTPO等四种升血小板药物临床应用评价及经济学评估[J].中国药物应用与监测,2010,7(1):5-9. |
| 作者姓名： | 郭代红 邢午宏 陈超 王伟兰 于力 刘皈阳 |
| 作者单位： | 1. 解放军总医院药品保障中心,北京,100853 2. 沈阳药科大学,辽宁,沈阳,110016 3. 解放军总医院血液科,北京,100853 |
| 基金项目： | 军队十一五科技攻关课题 |
| 摘 要： | 目的：评价rh-TPO、rhIL-11、复方皂矾丸、氨肽素四种升血小板药物用于各种血小板减少的疗效及经济学意义。方法：采用病例调查方法逐日锁定2009年2—5月间用药的住院病人共计265例，通过PASS系统追踪用药情况，评价疗效并观察用药安全性；数据资料采用SPSS软件进行对比性分析。结果：rhIL-11升血小板效果较好，也具有很好的成本效果比，其增量成本-效果比尤其有意义。rhTPO虽然效果最好，能短时间有效提高严重骨髓抑制导致的血小板下降，但成本-效果比较高。氨肽素的成本-效果比最低，但对重度骨髓抑制导致的血小板下降疗效不佳。结论：rhIL-11可以作为白血病患者等升血小板治疗的首选，rhTPO适用于有经济承受能力的患者，氨肽素建议用于血小板下降1、2级状态，如效果不明显可配合使用rhIL-11。 |
| 关 键 词： | 重组人血小板生成素 重组人白细胞介素-11 血小板 疗效 药物经济学 |
Evaluation of effectiveness and pharmacoeconomics of four elevating platelet drugs including rhTPO |
|
| Authors: | GUO Dai-hong XING Wu-hong CHEN Chao WANG Wei-lan YU Li LIU Gui-yang |
| Institution: | GUO Dai-hong1,XING Wu-hong2,CHEN Chao1,WANG Wei-lan1,YU Li3,LIU Gui-yang1(1. Department of Pharmaceutical Care,PLA General Hospital,Beijing 100853,China,2. Shenyang Pharmaceutical University,Shenyang 110016,3. Hematology Department,China) |
| Abstract: | Objective: To evaluate the effectiveness and pharmacoeconomics of four elevating platelet drugs including rhTPO, rhIL-11, compound Zaofan pills, ampeptide elemente on thrombopenia patients. Methods: Data of 265 inpatients using the four elevating platelet drugs were investigated by HIS from February to May in 2009. The curative effect and safety in drug use were analyzed. The data were computed by SPSS software. Results: Among the four drugs, effect of elevating platelet of rhIL-11 was good, with low cost-e... |
| Keywords: | rhTPO rhIL-11 Blood platelet Curative effect Pharmacoeconomics |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ | |